Homo sapiens EPH receptor A3 (EPHA3), transcript variant 1
EK4; ETK; ETK1; HEK; HEK4; TYRO4
A phospho specific peptide corresponding to residues surrounding Tyrosine 779 of human EphA3, Tyrosine 779 of EphA4, and Tyrosine 833 of EphA5 was used as an immunogen. This antibody only detects EphA3 phosphorylated at Tyrosine 779, EphA4 phosphorylated at Tyrosine 779, and EphA5 phosphorylated at Tyrosine 833.
Store at -20 °C. Buffer: Antibody buffer, sodium azide, glycerol, and BSA. Stable for 12 months from date of receipt.
Ephrin receptor tyrosine kinases (RTKs) and their ligands (ephrins) are highly conserved families that mediate cell movement during development (1). There are 14 known receptors, classed into either EphA or EphB, and 8 known ligands, classed into ephrin A or ephrin B. EphA receptors preferably interacts with glycosylphosphatidylinositol-linked ephrins (ephrin A), while EphB receptors preferably interacts with transmembrane ligands (ephrin B) (2). Multiple ligands are specific to each Ephrin receptors and cause receptor activation through transphosphorylation (3, 4). Both receptor and ligand-initiated signals can regulate repulsion, adhesion and de-adhesion mechanisms for the motility of adherent cells (5). Ephrin A3 (EphA3, Mek4, Hek, Hek4) binds to ephrin-A1 to A5 and ephrin-B1. A mutation in EphA3 has been linked to pathogenesis in several tumors, such as breast, lung, and pancreatic cancers (6). Tyrosine 779 of EphA3 is phosphorylated and required to mediate cell de-adhesion upon ephrin-A5 stimulation (7).
* Shipping is in business days
* OriGene provides validated application data and protocol, with money back guarantee.